Modus Therapeutics raises SEK 32 million to support further development.

Modus Therapeutics, a Stockholm, Sweden-based company focused on innovative treatments for patients with sickle cell disease, announced the successful completion of a financing round raising SEK 32 million from existing investors Karolinska Development, Östersjöstiftelsen and Praktikerinvest.

Modus Therapeutics, led by CEO Christina Herder, is a Swedish biotech company developing sevuparin – a new drug to treat people suffering from Sickle Cell Disease (SCD) – a painful, inherited blood disorder affecting millions of people around the globe. Sickle Cell Disease patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain and the amount of time they will need to spend in hospital.

Modus plans to develop an administration form of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care.